BRIEF-Harmony Biosciences Announces Initiation Of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (Bp1.15205) For Central Disorders Of Hypersomnolence

Reuters11-19

BRIEF-<a href="https://laohu8.com/S/HRMY">Harmony Biosciences</a> Announces Initiation Of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (Bp1.15205) For Central Disorders Of Hypersomnolence

Harmony Biosciences Holdings Inc HRMY.O:

HARMONY BIOSCIENCES ANNOUNCES INITIATION OF FIRST-IN-HUMAN STUDY WITH POTENTIAL BEST-IN-CLASS OREXIN 2 RECEPTOR AGONIST (BP1.15205) FOR CENTRAL DISORDERS OF HYPERSOMNOLENCE
HARMONY BIOSCIENCES - TOPLINE DATA EXPECTED IN 2026

Source text: ID:nBw4BqhH2a

Further company coverage: HRMY.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584421909?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 22:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584421909","market":"nz","top_or_hot":-1,"title":"BRIEF-Harmony Biosciences Announces Initiation Of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (Bp1.15205) For Central Disorders Of Hypersomnolence","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/HRMY\">Harmony Biosciences</a> Announces Initiation Of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (Bp1.15205) For Central Disorders Of Hypersomnolence</title></head><body><p>Harmony Biosciences Holdings Inc <span>HRMY.O</span>:</p><ul><li><p>HARMONY BIOSCIENCES ANNOUNCES INITIATION OF FIRST-IN-HUMAN STUDY WITH POTENTIAL BEST-IN-CLASS OREXIN 2 RECEPTOR AGONIST (BP1.15205) FOR CENTRAL DISORDERS OF HYPERSOMNOLENCE</p></li><li><p>HARMONY BIOSCIENCES - TOPLINE DATA EXPECTED IN 2026</p></li></ul><p>Source text: <span>ID:nBw4BqhH2a</span></p><p>Further company coverage: <span>HRMY.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Harmony Biosciences Announces Initiation Of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (Bp1.15205) For Central Disorders Of Hypersomnolence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Harmony Biosciences Announces Initiation Of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (Bp1.15205) For Central Disorders Of Hypersomnolence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-19 22:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/HRMY\">Harmony Biosciences</a> Announces Initiation Of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (Bp1.15205) For Central Disorders Of Hypersomnolence</title></head><body><p>Harmony Biosciences Holdings Inc <span>HRMY.O</span>:</p><ul><li><p>HARMONY BIOSCIENCES ANNOUNCES INITIATION OF FIRST-IN-HUMAN STUDY WITH POTENTIAL BEST-IN-CLASS OREXIN 2 RECEPTOR AGONIST (BP1.15205) FOR CENTRAL DISORDERS OF HYPERSOMNOLENCE</p></li><li><p>HARMONY BIOSCIENCES - TOPLINE DATA EXPECTED IN 2026</p></li></ul><p>Source text: <span>ID:nBw4BqhH2a</span></p><p>Further company coverage: <span>HRMY.O</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HRMY","symbol_name":"Harmony Biosciences Holdings, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV0R5:1","article_id":"2584421909","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584421909","pubTimestamp":1763561552,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Harmony Biosciences Announces Initiation Of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (Bp1.15205) For Central Disorders Of HypersomnolenceHarmony Biosciences Ho","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HRMY":"Harmony Biosciences Holdings, Inc.","BK4007":"制药"},"translate_title":"BRIEF-Harmony Biosciences宣布启动潜在同类最佳食欲素2受体激动剂(Bp1.15205)治疗中枢性嗜睡症的首项人体研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRMY":0.9},"content_text":"BRIEF-Harmony Biosciences Announces Initiation Of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (Bp1.15205) For Central Disorders Of HypersomnolenceHarmony Biosciences Holdings Inc HRMY.O:HARMONY BIOSCIENCES ANNOUNCES INITIATION OF FIRST-IN-HUMAN STUDY WITH POTENTIAL BEST-IN-CLASS OREXIN 2 RECEPTOR AGONIST (BP1.15205) FOR CENTRAL DISORDERS OF HYPERSOMNOLENCEHARMONY BIOSCIENCES - TOPLINE DATA EXPECTED IN 2026Source text: ID:nBw4BqhH2aFurther company coverage: HRMY.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584421909","isCrawlerRequest":true}